Device Trial Radar · NCT02401555
Performance Evaluation of the Bio-Rad Geenius HIV1/2 Supplemental Assay
Last checked: Nov 20, 2026Latest source record: Mar 28, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
419
Actual
Start
Apr 2013
Primary completion
Dec 2013
Study completion Dec 2013
Sponsor
- Lead sponsor
- Bio-Rad LaboratoriesNot on our public-company list
- Sponsor type
- Industry
- First posted
- Mar 30, 2015
Design
- Study type
- Observational
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study was to evaluate the performance of the Bio-Rad Geenius HIV 1/2 Supplemental Assay, a single-use immunochromatographic assay for the confirmation and differentiation of individual antibodies to Human Immunodeficiency Virus Types 1 and 2 (HIV-1 and HIV-2) in fingerstick whole blood, venous whole blood, serum, or plasma samples (EDTA, heparin, and sodium citrate).
Conditions
- HIV
Interventions
Geenius HIV1/2 Supplemental AssayDevice
The purpose of this study is to evaluate the performance of the Bio-Rad Geenius HIV1/2 Supplemental Assay test in finger stick whole blood, venous whole blood, serum or plasma (EDTA, heparin, sodium citrate).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Diagnostic Result of Assay (Bio-Rad Geenius HIV 1/2 Supplemental Assay) From Accuracy AnalysisTime frame: Up to 9 months
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
HIV/AIDS Division, San Fransisco General Hospital
San Francisco, California
Blood Systems Research Institute
San Francisco, California
Center for Disease Control and Prevention
Atlanta, Georgia
2 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.